| Literature DB >> 34950103 |
Fang Zhong1,2,3, Liying Guan4, Haiyan Lin4, Meng Zhao2,3,5, Yiming Qin6, Qihang Li1,2,3, Zhongshang Yuan7, Guang Yang8, Ling Gao1,2,3,5, Jiajun Zhao1,2,3,5.
Abstract
Objective: Nonalcoholic fatty liver disease (NAFLD) is becoming a global public health challenge. A convenient NAFLD indicator will greatly facilitate risk appraisal and prevention. As a readily available and inexpensive hematological index in routine clinical examinations, red blood cells (RBCs) are gaining increasing attention in many diseases, such as metabolic syndrome, but their association with NAFLD is unknown.Entities:
Keywords: generalized estimating equation; indicator; longitudinal cohort study; nonalcoholic fatty liver disease; red blood cell; risk factor
Mesh:
Substances:
Year: 2021 PMID: 34950103 PMCID: PMC8688742 DOI: 10.3389/fendo.2021.760981
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 5.555
Figure 1Participant flow diagram.
Baseline characteristics of study subjects based on NAFLD status.
| Characteristic | NAFLD or Not | Degree of NAFLD | |||||
|---|---|---|---|---|---|---|---|
| Non-NAFLD | NAFLD | P Value | Mild NAFLD | Moderate NAFLD | Severe NAFLD | P Value | |
| Participants (%) | 17,383 (64.1) | 9729 (35.9) | 6934 (71.3) | 2542 (26.1) | 253 (2.6) | ||
| Age, y | 42 (21) | 47 (18) | <0.001 | 48 (18) | 46 (17) | 43 (22) | <0.001 |
| Sex (%) | <0.001 | <0.001 | |||||
| Men | 9310 (53.6) | 8057 (82.8) | 5683 (82.0) | 2153 (84.7) | 221 (87.4) | ||
| Women | 8073 (46.4) | 1672 (17.2) | 1251 (18.0) | 389 (15.3) | 32 (12.6) | ||
| RBC, cells×1012/L | 4.80 ± 0.45 | 5.07 ± 0.40 | <0.001 | 5.05 ± 0.40 | 5.12 ± 0.39 † | 5.13 ± 0.44 † | <0.001 |
| Hb, g/L | 146 (23) | 156 (16) | <0.001 | 156 (16) | 158 (15) † | 157 (14) | <0.001 |
| Diet (%) | <0.001 | <0.001 | |||||
| Vegetarian | 3579 (20.6) | 1317 (13.5) | 996 (14.4) | 298 (11.7) | 23 (9.1) | ||
| Dishes mix | 12,583 (72.4) | 7111 (73.1) | 5096 (73.5) | 1838 (72.3) | 177 (70.0) | ||
| Meatatarian | 1221 (7.0) | 1301 (13.4) | 842 (12.1) | 406 (16.0) | 53 (20.9) | ||
| Smoking (%) | <0.001 | <0.001 | |||||
| Non-smoker | 13,997 (80.5) | 6298 (64.7) | 4503 (64.9) | 1634 (64.3) | 161 (63.6) | ||
| Smoker | 3386 (19.5) | 3431 (35.3) | 2431 (35.1) | 908 (35.7) | 92 (26.4) | ||
| Exercise (%) | 0.466 | <0.001 | |||||
| Occasionally | 12,687 (73.0) | 7070 (72.6) | 4930 (71.1) | 1920 (75.5) | 210 (83.0) | ||
| Regularly | 4696 (27.0) | 2669 (27.4) | 2004 (28.9) | 622 (24.5) | 43 (17.0) | ||
| BMI, kg/m2 | 23.36 ± 2.93 | 27.06 ± 2.88 | <0.001 | 26.53 ± 2.60 | 28.18 ± 3.00 † | 30.41 ± 3.54 † ‡ | <0.001 |
| SBP, mmHg | 116 (24) | 128 (22) | <0.001 | 127 (22) | 131 (21) † | 135(21) † ‡ | <0.001 |
| FPG, mmol/L | 5.10 (0.72) | 5.44 (1.04) | <0.001 | 5.38 (0.93) | 5.62 (1.22) † | 5.73 (1.96) † ‡ | <0.001 |
| TG, mmol/L | 0.99 (0.65) | 1.69 (1.17) | <0.001 | 1.60 (1.08) | 1.94 (1.41) † | 2.21 (1.52) † | <0.001 |
| TC, mmol/L | 5.00 ± 0.92 | 5.36 ± 0.97 | <0.001 | 5.32 ± 0.95 | 5.45 ± 0.99 † | 5.46 ± 1.03 | <0.001 |
| HDL-C, mmol/L | 1.43 ± 0.34 | 1.21 ± 0.26 | <0.001 | 1.23 ± 0.26 | 1.17 ± 0.25 † | 1.13 ± 0.23 † | <0.001 |
| LDL-C, mmol/L | 2.86 ± 0.79 | 3.19 ± 0.84 | <0.001 | 3.17 ± 0.82 | 3.23 ± 0.87 † | 3.24 ± 0.88 | <0.001 |
| AST, IU/L | 20 (6) | 23 (7) | <0.001 | 22 (7) | 25 (12) † | 29 (14) † ‡ | <0.001 |
| ALT, IU/L | 17 (10) | 26 (17) | <0.001 | 24 (15) | 33 (25) † | 47 (36) † ‡ | <0.001 |
NAFLD, non-alcoholic fatty liver disease; Non-NAFLD, without NAFLD; y, years; RBC, red blood cell; Hb, hemoglobin; BMI, body mass index; SBP, systolic blood pressure; FPG, fasting plasma glucose; TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; AST, aspartate aminotransferase; ALT, alanine aminotransferase.
Data with normal distributions are reported using mean ± standard deviation; data with nonnormal distributions are reported using median (interquartile range); data with categorical variables are reported using number (percent). †P < 0.05 vs mild NAFLD; ‡P < 0.05 vs moderate NAFLD.
Figure 2Prevalence of NAFLD at each visit time point. 20121, 20122, 20131,20132, ……20161,20162 represent the first half of 2012, the second half of 2012, the first half of 2013, the second half of 2013, …… the first half of 2016, and the second half of 2016. Q1, Q2, Q3, Q4 represent the lowest quartile, second quartile, third quartile, highest quartile of RBC count respectively.
Figure 3Distribution of incident NAFLD cases and different severity of incident NAFLD cases over RBC count quartiles. Q1, Q2, Q3, Q4 represent the lowest quartile, second quartile, third quartile, highest quartile of RBC count respectively.
Figure 4Incidence density and GEE analysis for incident NAFLD based on RBC count during follow-up. Q1, the lowest quartile of RBC count (<4.83×1012cells/L for men, <4.33×1012cells/L for women); Q2, the second quartile of RBC count (4.83-5.08×1012cells/L for men, 4.33-4.52×1012cells/L for women); Q3, the third quartile of RBC count (5.09-5.32×1012cells/L for men, 4.53-4.74×1012cells/L for women); Q4, the highest quartile of RBC count (>5.32×1012cells/L for men, >4.74×1012cells/L for women). Model 1 was adjusted for age, follow-up time. Model 2 was adjusted for age, BMI, SBP, GLU, TG, HDL-C, LDL-C, diet, smoking, exercise, follow-up time, and residual errors of regressing Hb on RBC. Sex was also adjusted in all models of the total group.
GEE analysis for severity of incident NAFLD based on RBC count during follow-up.
| Unadjusted | Model 1 | Model 2 | ||||
|---|---|---|---|---|---|---|
| OR (95% CI) | P Value | OR (95% CI) | P Value | OR (95% CI) | P Value | |
|
| ||||||
| Continuous | 2.53 (2.37-2.71) | <0.001 | 2.19 (1.05-2.00) | <0.001 | 1.51 (1.36-1.68) | <0.001 |
| Q1 | 1 [Reference] | 1 [Reference] | 1 [Reference] | |||
| Q2 | 1.78 (1.61-1.96) | <0.001 | 1.68 (1.51-1.87) | <0.001 | 1.43 (1.28-1.60) | <0.001 |
| Q3 | 2.63 (2.38-2.91) | <0.001 | 2.21 (1.97-2.49) | <0.001 | 1.57 (1.39-1.79) | <0.001 |
| Q4 | 3.35 (3.03-3.70) | <0.001 | 2.75 (2.43-3.12) | <0.001 | 1.67 (1.45-1.93) | <0.001 |
| | <0.001 | <0.001 | <0.001 | |||
|
| ||||||
| Continuous | 1.73 (1.57-1.90) | <0.001 | 1.77 (1.58-1.97) | <0.001 | 1.30 (1.15-1.48) | <0.001 |
| Q1 | 1 [Reference] | 1 [Reference] | 1 [Reference] | |||
| Q2 | 1.42 (1.18-1.71) | <0.001 | 1.60 (1.30-1.96) | <0.001 | 1.32 (1.07-1.63) | 0.01 |
| Q3 | 1.76 (1.47-2.12) | <0.001 | 1.98 (1.62-2.43) | <0.001 | 1.42 (1.15-1.76) | 0.001 |
| Q4 | 2.07 (1.73-2.49) | <0.001 | 2.35 (1.91-2.90) | <0.001 | 1.49 (1.20-1.85) | <0.001 |
| | <0.001 | <0.001 | 0.001 | |||
|
| ||||||
| Continuous | 2.84 (2.41-3.35) | <0.001 | 2.82 (2.37-3.35) | <0.001 | 2.00 (1.64-2.44) | <0.001 |
| Q1 | 1 [Reference] | 1 [Reference] | 1 [Reference] | |||
| Q2 | 1.63 (1.44-1.83) | <0.001 | 1.73 (1.52-1.97) | <0.001 | 1.44 (1.25-1.66) | 0.004 |
| Q3 | 2.19 (1.89-2.54) | <0.001 | 2.25 (1.92-2.64) | <0.001 | 1.60 (1.34-1.91) | 0.010 |
| Q4 | 2.65 (2.09-3.36) | <0.001 | 2.53 (1.94-3.30) | <0.001 | 1.73 (1.29-2.32) | 0.027 |
| | <0.001 | <0.001 | <0.001 | |||
OR, odds ratio; 95% CI, 95% confidence interval; Q1, the lowest quartile of RBC count (<4.83×1012cells/L for men, <4.33×1012cells/L for women); Q2, the second quartile of RBC count (4.83-5.08×1012cells/L for men, 4.33-4.52×1012cells/L for women); Q3, the third quartile of RBC count (5.09-5.32×1012cells/L for men, 4.53-4.74×1012cells/L for women); Q4, the highest quartile of RBC count (>5.32×1012cells/L for men, >4.74×1012cells/L for women).
Model 1 was adjusted for age, follow-up time. Model 2 was adjusted for age, BMI, SBP, GLU, TG, HDL-C, LDL-C, diet, smoking, exercise, follow-up time, and residual errors of regressing Hb on RBC. Sex was also adjusted in Model 1 and Model 2 of the total group.
GEE analysis for NAFLD progression based on RBC count during follow-up.
| Unadjusted | Model 1 | Model 2 | ||||
|---|---|---|---|---|---|---|
| OR (95% CI) | P Value | OR (95% CI) | P Value | OR (95% CI) | P Value | |
|
| ||||||
| Continuous | 1.58 (1.40-1.77) | <0.001 | 1.72 (1.51-1.96) | <0.001 | 1.53 (1.32-1.77) | <0.001 |
| Q1 | 1 [Reference] | 1 [Reference] | 1 [Reference] | |||
| Q2 | 1.25 (1.09-1.44) | 0.002 | 1.26 (1.10-1.45) | <0.001 | 1.19 (1.03-1.37) | 0.016 |
| Q3 | 1.44 (1.25-1.66) | <0.001 | 1.42 (1.23-1.64) | <0.001 | 1.31 (1.13-1.51) | <0.001 |
| Q4 | 1.83 (1.59-2.10) | <0.001 | 1.72 (1.49-1.98) | <0.001 | 1.52 (1.31-1.77) | <0.001 |
|
| <0.001 | <0.001 | 0.001 | |||
|
| ||||||
| Continuous | 1.74 (1.51-2.00) | <0.001 | 1.59 (1.37-1.84) | <0.001 | 1.41 (1.20-1.66) | <0.001 |
| Q1 | 1 [Reference] | 1 [Reference] | 1 [Reference] | |||
| Q2 | 1.20 (1.03-1.40) | 0.018 | 1.20 (1.03-1.40) | 0.019 | 1.14 (0.98-1.34) | 0.090 |
| Q3 | 1.41 (1.20-1.64) | <0.001 | 1.37 (1.17-1.61) | <0.001 | 1.27 (1.08-1.49) | 0.005 |
| Q4 | 1.75 (1.51-2.05) | <0.001 | 1.62 (1.39-1.90) | <0.001 | 1.45 (1.23-1.72) | <0.001 |
|
| <0.001 | <0.001 | 0.001 | |||
|
| ||||||
| Continuous | 2.51 (1.83-3.44) | <0.001 | 2.30 (1.66-3.17) | <0.001 | 2.10 (1.48-2.96) | 0.081 |
| Q1 | 1 [Reference] | 1 [Reference] | 1 [Reference] | |||
| Q2 | 1.46 (1.06-2.03) | 0.022 | 1.47 (1.08-2.02) | 0.017 | 1.38 (1.00-1.91) | 0.048 |
| Q3 | 1.57 (1.14-2.15) | 0.006 | 1.51 (1.10-2.08) | 0.011 | 1.41 (1.02-1.96) | 0.037 |
| Q4 | 2.12 (1.54-2.91) | <0.001 | 1.96 (1.42-2.71) | <0.001 | 1.72 (1.24-2.40) | 0.001 |
|
| <0.001 | <0.001 | 0.002 | |||
OR, odds ratio; 95% CI, 95% confidence interval; Q1, the lowest quartile of RBC count (<4.92×1012cells/L for men, <4.49×1012cells/L for women); Q2, the second quartile of RBC count (4.92-5.16×1012cells/L for men, 4.49-4.67×1012cells/L for women); Q3, the third quartile of RBC count (5.17-5.40×1012cells/L for men, 4.68-4.88×1012cells/L for women); Q4, the highest quartile of RBC count (>5.40×1012cells/L for men, >4.88×1012cells/L for women).
Model 1 was adjusted for adjustment for age, follow-up time. Model 2 was adjusted for age, BMI, SBP, GLU, TG, HDL-C, LDL-C, Hb, diet, smoking, exercise, follow-up time, severity of NAFLD at baseline, and residual errors of regressing Hb on RBC. Sex was also adjusted in Model 1 and Model 2 of the total group.